Comparative Efficacy of Peptides vs. Traditional Anabolics

Why this comparison is lopsided

Lifters often ask whether peptides can stand in for steroids or SARMs. The answer depends on the goal, and on how much human evidence sits behind each side. Testosterone has been tested in randomized trials at the high doses lifters use. Most performance peptides have only animal data or short hormone studies.

Anabolic-androgenic steroids (AAS) and selective androgen receptor modulators (SARMs) both act on the androgen receptor. The peptides usually compared with them work elsewhere: growth hormone secretagogues push the pituitary to release more growth hormone (GH), and repair peptides such as BPC-157 and TB-500 act on healing pathways studied mostly in rodents. This page goes goal by goal and says what was measured, and in whom. For a closer look at the receptor biology, see our mechanism-focused comparison of peptides and AAS.

Muscle and strength: what anabolics do in trials

Testosterone binds the androgen receptor in muscle and raises muscle protein synthesis directly. In a 1996 randomized trial published in the New England Journal of Medicine, 43 healthy men received 600 mg of testosterone enanthate or placebo by injection each week for 10 weeks. Men who got testosterone and lifted gained about 6.1 kg of fat-free mass and added about 22 kg to their bench press and 38 kg to their squat. Even the men on testosterone who didn't train gained more muscle and strength than men on placebo. That dose is several times a replacement dose, but the Endocrine Society's 2014 statement on performance-enhancing drugs notes that users often take doses this far above normal.

SARMs were designed to activate the same receptor more selectively in muscle and bone, and their human data are much thinner. In a 21-day placebo-controlled trial, 76 healthy men took the SARM LGD-4033 at 0.1, 0.3 or 1 mg a day. Lean body mass rose with dose, while fat mass didn't change significantly. Total testosterone and HDL cholesterol fell, then returned to baseline after stopping. Three weeks of small doses says little about longer use.

Muscle and strength: what GH peptides do

Growth hormone secretagogues come in two groups. GHRH analogs such as CJC-1295 and Mod GRF 1-29 mimic growth hormone-releasing hormone. GHRPs such as ipamorelin, GHRP-2 and GHRP-6 act on the ghrelin receptor. Both raise the body's own GH output, and GH in turn raises IGF-1.

The hormone response is real. In two placebo-controlled 2006 trials in healthy adults, one subcutaneous injection of CJC-1295 raised average GH levels 2- to 10-fold for at least six days and IGF-1 levels 1.5- to 3-fold for 9-11 days. As of October 2026, though, we found no published trial that measured muscle size or strength in people taking CJC-1295, ipamorelin, GHRP-2 or GHRP-6.

The closest evidence comes from related compounds. A 2008 systematic review of randomized trials that gave GH itself to young, fit adults (303 people on GH) found about 2.1 kg more lean body mass than in controls, but no clear gain in strength or exercise capacity, and more fluid retention and fatigue. Some of that lean mass may be water. In a two-year trial of MK-677, an oral GH secretagogue that isn't a peptide, 65 older adults taking 25 mg a day gained about 1.1 kg of fat-free mass while the placebo group lost a little, with no change in strength or function. Fasting glucose rose and insulin sensitivity fell.

Community reports broadly match this: users on peptide forums tend to describe gradual changes in body composition and recovery over months, not fast increases in size.

Injury repair: rodent data and a human risk signal

This is where peptides are most often said to beat anabolics. On the anabolic side, the clearest human signal is harm. In a 2015 study of 142 experienced male bodybuilders, 22% of men with at least two years of AAS use reported a tendon rupture, compared with 6% of non-users. Upper-body ruptures occurred only in the AAS group. The data were self-reported and observational, so they show an association, not proof of cause.

On the peptide side, the data come mostly from animals. A systematic review of BPC-157 in orthopaedic sports medicine, covering studies through mid-2024, included 36 studies, 35 of them preclinical. In those animal models BPC-157 improved healing of muscle, tendon, ligament and bone, with angiogenesis among the proposed mechanisms. The one clinical study was an uncontrolled retrospective series in which 7 of 12 people reported knee-pain relief lasting over six months. The reviewers found no clinical safety data. As of October 2026, a University of Arkansas Phase 1 trial of BPC-157 after rotator cuff repair surgery is registered (about 30 participants, planned start January 2027), but it isn't recruiting yet.

TB-500 has even less behind it. It's a short synthetic fragment of thymosin beta-4 (sequence LKKTETQ), not the whole protein, and FDA says it has found no human exposure data for products containing the fragment. Trials of full-length thymosin beta-4 don't carry over to it.

The site rates BPC-157's evidence as emerging and TB-500's as preliminary. Users report mixed results with both: some describe faster recovery from tendon and joint injuries, while others notice nothing after several weeks. Part of that gap may be product quality, since gray-market vials vary, and part may be that no controlled human trial has measured tendon healing with either peptide.

Fat loss: AOD-9604's trial record

AOD-9604 is a modified fragment of GH (amino acids 176-191), developed as an obesity drug and still marketed to lifters for targeted fat loss. Its human trials didn't support that. According to FDA's 2024 review for its compounding advisory committee, the sponsor's Phase 2b trial enrolled 536 adults with obesity and gave oral AOD-9604 at 0.25, 0.5 or 1 mg a day, or placebo. It found no significant difference in weight loss at 12 weeks, the primary endpoint, and the company ended development for obesity in 2007. Those trials used oral or IV dosing. FDA found no human data for injected AOD-9604, which is how users take it, and users mostly report little or no change.

Anabolics aren't fat-loss drugs either; in the three-week LGD-4033 trial, fat mass didn't change. For this goal, neither class has good evidence in healthy lifters.

Sleep and recovery

Delta sleep-inducing peptide (DSIP) is sold for sleep, but its trial record is old and weak. In a 1992 double-blind study, 16 people with chronic insomnia received DSIP (25 nmol/kg by IV infusion) or placebo before three nights in a sleep lab. Sleep efficiency and time to fall asleep improved slightly. The authors judged those effects weak and possibly due to chance changes in the placebo group, and concluded that DSIP was "not likely to be of major therapeutic benefit."

Users often say ipamorelin deepens their sleep. We found no trial that measured sleep with ipamorelin, so that claim rests on user reports.

Efficacy by goal

The Endocrine Society's statement links performance-enhancing drug use, including AAS, to a higher risk of death and to disorders across most organ systems, from the heart and liver to mood and tendons. Suppression of natural testosterone can last: in a 2016 case-control study, former AAS users had lower testosterone and more hypogonadal symptoms years after stopping. Peptide risks are less known, which isn't the same as low. FDA says it lacks enough safety information to know whether BPC-157 or the TB-500 fragment would cause harm in people, and it has noted serious adverse events with CJC-1295, including raised heart rate and a vasodilatory reaction. Our long-term health comparison of peptides, steroids and SARMs covers this in more depth.

Combining the two

Many lifters don't treat this as either-or. Users commonly describe adding BPC-157 during heavy training blocks or steroid cycles in the hope of protecting tendons, and adding GH secretagogues during a cruise or post-cycle therapy (PCT). No study has tested either combination. GH secretagogues act on the GH axis, not the hormone axis that controls testosterone production, and we found no study showing they help testosterone recover after a cycle.

For tested athletes, the efficacy comparison matters less than the rules. As of October 2026, WADA's 2026 Prohibited List bans each of the following at all times: AAS (S1.1), SARMs (S1.2), BPC-157 (S0), TB-500 (S2.3), AOD-9604 (S2.2.3), and CJC-1295, ipamorelin and the GHRPs (S2.2.4). Our guide to peptides and anti-doping rules covers testing in more detail.

What we still don't know

• Whether any GH secretagogue changes muscle size or strength in trained adults. We found no trial that has tested it.
• Whether BPC-157's rodent results carry over to human tendon healing. The Arkansas trial, if it runs, will be small and limited to recovery after surgery.
• What's in a given vial. Research findings assume the labeled compound at the labeled amount, and gray-market products don't guarantee either.
• Long-term safety. There are no long-term human safety data for BPC-157, TB-500 or the GHRPs, while the harms of AAS have been studied in users for decades.